Sumit Chanda - A Shared Approach to Drug Discovery: Sanford Burnham and Model Medicines Collaboration (EP.03)
Sumit Chanda and Daniel Haders II, Ph.D. discuss the recent collaboration between the Sanford Burnham Prebys Medical Discovery Institute and Model Medicines in Ep. 3 of our four-part series. They discuss the inception of their collaboration, the process of taking therapeutics from bench to bedside, and their shared approach to drug discovery.
Model Medicines recently partnered with the Chanda Lab at Sanford Burnham Prebys Medical Discovery Institute to discover and develop new treatments for COVID-19 and other infectious diseases.
Sumit Chanda earned his Ph.D from Stanford University in 2001, and received his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF). He subsequently transitioned to a Group Leader position, and established his research group in the Division of Cellular Genomics at GNF. In 2007, he joined the Infectious and Inflammatory Disease Center at Sanford-Burnham Medical Research Institute as an Associate Professor. Dr. Chanda was promoted to Professor in 2013. In 2015, he was appointed Director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys Medical Discovery Institute.
